array:25 [
  "pii" => "S2013251416301304"
  "issn" => "20132514"
  "doi" => "10.1016/j.nefroe.2016.12.003"
  "estado" => "S300"
  "fechaPublicacion" => "2016-11-01"
  "aid" => "246"
  "copyright" => "Sociedad Española de Nefrología"
  "copyrightAnyo" => "2016"
  "documento" => "simple-article"
  "crossmark" => 0
  "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
  "subdocumento" => "cor"
  "cita" => "Nefrologia (English Version). 2016;36:705"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 2621
    "formatos" => array:3 [
      "EPUB" => 342
      "HTML" => 1792
      "PDF" => 487
    ]
  ]
  "Traduccion" => array:1 [
    "en" => array:20 [
      "pii" => "S0211699516301114"
      "issn" => "02116995"
      "doi" => "10.1016/j.nefro.2016.06.010"
      "estado" => "S300"
      "fechaPublicacion" => "2016-11-01"
      "aid" => "246"
      "copyright" => "Sociedad Española de Nefrología"
      "documento" => "simple-article"
      "crossmark" => 0
      "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
      "subdocumento" => "cor"
      "cita" => "Nefrologia. 2016;36:705"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 3733
        "formatos" => array:3 [
          "EPUB" => 406
          "HTML" => 2530
          "PDF" => 797
        ]
      ]
      "en" => array:10 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
        "titulo" => "Comment on &#8220;Cellular and molecular aspects of diabetic nephropathy&#59; the role of VEGF-A&#8221;"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "paginas" => array:1 [
          0 => array:1 [
            "paginaInicial" => "705"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "es" => array:1 [
            "titulo" => "Comentario a &#8220;Cellular and molecular aspects of diabetic nephropathy&#59; the role of VEGF-A&#8221;"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Erol Arslan, Adem Ayd&#305;n, &#350;eref Demirba&#351;, Kenan Sa&#287;lam"
            "autores" => array:4 [
              0 => array:2 [
                "nombre" => "Erol"
                "apellidos" => "Arslan"
              ]
              1 => array:2 [
                "nombre" => "Adem"
                "apellidos" => "Ayd&#305;n"
              ]
              2 => array:2 [
                "nombre" => "&#350;eref"
                "apellidos" => "Demirba&#351;"
              ]
              3 => array:2 [
                "nombre" => "Kenan"
                "apellidos" => "Sa&#287;lam"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2013251416301304"
          "doi" => "10.1016/j.nefroe.2016.12.003"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251416301304?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699516301114?idApp=UINPBA000064"
      "url" => "/02116995/0000003600000006/v1_201611240148/S0211699516301114/v1_201611240148/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:20 [
    "pii" => "S2013251417300135"
    "issn" => "20132514"
    "doi" => "10.1016/j.nefroe.2017.01.010"
    "estado" => "S300"
    "fechaPublicacion" => "2016-11-01"
    "aid" => "248"
    "copyright" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
    "documento" => "simple-article"
    "crossmark" => 0
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "cor"
    "cita" => "Nefrologia &#40;English Version&#41;. 2016;36:706-7"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 3899
      "formatos" => array:3 [
        "EPUB" => 363
        "HTML" => 2738
        "PDF" => 798
      ]
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
      "titulo" => "Reply to letter to editor comment on &#8220;Cellular and molecular aspects of diabetic nephropathy&#59; the role of VEGF-A&#8221;"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "706"
          "paginaFinal" => "707"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Respuesta a la carta al editor referida a &#171;Mecanismos celulares y moleculares de la nefropat&#237;a diab&#233;tica&#44; rol del VEGF-A&#187;"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Delma Veron, Alda Tufro"
          "autores" => array:2 [
            0 => array:2 [
              "nombre" => "Delma"
              "apellidos" => "Veron"
            ]
            1 => array:2 [
              "nombre" => "Alda"
              "apellidos" => "Tufro"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0211699516301138"
        "doi" => "10.1016/j.nefro.2016.08.001"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699516301138?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251417300135?idApp=UINPBA000064"
    "url" => "/20132514/0000003600000006/v1_201702210030/S2013251417300135/v1_201702210030/en/main.assets"
  ]
  "itemAnterior" => array:20 [
    "pii" => "S201325141630133X"
    "issn" => "20132514"
    "doi" => "10.1016/j.nefroe.2016.05.009"
    "estado" => "S300"
    "fechaPublicacion" => "2016-11-01"
    "aid" => "235"
    "copyright" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
    "documento" => "simple-article"
    "crossmark" => 0
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "crp"
    "cita" => "Nefrologia &#40;English Version&#41;. 2016;36:701-4"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 4655
      "formatos" => array:3 [
        "EPUB" => 314
        "HTML" => 3772
        "PDF" => 569
      ]
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Case report</span>"
      "titulo" => "Failed ABO incompatible high titers kidney transplant using bortezomib&#46; Case report"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "701"
          "paginaFinal" => "704"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Fracaso en el uso de bortezomib en el trasplante ABO incompatible con titulos altos&#46; Reporte de un caso"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Fig&#46; 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1475
              "Ancho" => 2167
              "Tamanyo" => 206242
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Desensitization protocol&#44; including the three phases of consecutive treatment&#46; RTX&#44; rituximab&#59; BTZ&#44; bortezomib&#59; PE&#44; plasma exchange&#59; IVIG intravenous immunoglobulins&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Erika De Sousa-Amorim, Ignacio Revuelta, Fritz Diekmann, Joan Cid, Miquel Lozano, Federic Oppenheimer"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "Erika"
              "apellidos" => "De Sousa-Amorim"
            ]
            1 => array:2 [
              "nombre" => "Ignacio"
              "apellidos" => "Revuelta"
            ]
            2 => array:2 [
              "nombre" => "Fritz"
              "apellidos" => "Diekmann"
            ]
            3 => array:2 [
              "nombre" => "Joan"
              "apellidos" => "Cid"
            ]
            4 => array:2 [
              "nombre" => "Miquel"
              "apellidos" => "Lozano"
            ]
            5 => array:2 [
              "nombre" => "Federic"
              "apellidos" => "Oppenheimer"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S0211699516300868"
        "doi" => "10.1016/j.nefro.2016.05.022"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699516300868?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S201325141630133X?idApp=UINPBA000064"
    "url" => "/20132514/0000003600000006/v1_201702210030/S201325141630133X/v1_201702210030/en/main.assets"
  ]
  "en" => array:12 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
    "titulo" => "Comment on &#8220;Cellular and molecular aspects of diabetic nephropathy&#59; the role of VEGF-A&#8221;"
    "tieneTextoCompleto" => true
    "saludo" => "Dear Editor&#44;"
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "705"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Erol Arslan, Adem Ayd&#305;n, &#350;eref Demirba&#351;, Kenan Sa&#287;lam"
        "autores" => array:4 [
          0 => array:4 [
            "nombre" => "Erol"
            "apellidos" => "Arslan"
            "email" => array:1 [
              0 => "earslan89&#64;yahoo&#46;com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:2 [
            "nombre" => "Adem"
            "apellidos" => "Ayd&#305;n"
          ]
          2 => array:2 [
            "nombre" => "&#350;eref"
            "apellidos" => "Demirba&#351;"
          ]
          3 => array:2 [
            "nombre" => "Kenan"
            "apellidos" => "Sa&#287;lam"
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Department of Internal Medicine&#44; G&#252;lhane Military Medical Academy&#44; Ankara&#44; Turkey"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "<span class="elsevierStyleItalic">Corresponding author</span>&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Comentario a &#8220;Cellular and molecular aspects of diabetic nephropathy&#59; the role of VEGF-A&#8221;"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">We read the published article with the title of &#8216;Cellular and molecular aspects of diabetic nephropathy&#59; the role of VEGF-A&#8217;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">1</span></a> with a great interest and we found worth sharing our clinical observations through a case to contribute to the their determination&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">Katherine Carranza et al&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">1</span></a> have stated that the experimental conditions VEGF-A decreased or after treatment with molecules developed against VEGF&#44; it can be observed various pathologic processes such as glomerular basement membrane damage&#44; proteinuria&#44; acute renal failure and thromboembolic events&#46; Monoclonal antibodies that bind the VEGF has long been used in systemic treatment protocol of solid tumors&#46; Recently&#44; by ophthalmologists&#44; intravitreal administration of anti-VEGF agents seen as the primary treatment method in conditions of age- related macular degeneration&#44; diabetic retinopathy&#44; retinal vein occlusion&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">2</span></a> Although systemic side effects are well known with the high dose intravenous use in cancer therapy&#44; almost local side effects were reported associated with intraocular anti-VEGF treatment&#46; However&#44; despite the blood retinal barrier&#44; anti-VEGF agents are detectable in systemic circulation after intraocular administration through uveal vessels or by aqueous humor outflow and might constitutes systemic adverse effect like nephropathy by antagonizing to VEGF-dependent pathway in glomeruli&#46;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">3</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">We describe a case of nephrotic syndrome that were unable to detect significant findings for etiology in first research&#46; But with detailed history we found that she had received intravitreal anti-VEGF due to diabetic retinopathy 10 days before the occurrence of symptoms&#46; After the exclusion of other possible causes&#46; We thought anti-VEGF agents might be responsible&#46; In the literature&#44; we found only 3 cases associated with renal toxicity of intraocular anti-VEGF therapy&#46;<a class="elsevierStyleCrossRefs" href="#bib0050"><span class="elsevierStyleSup">4&#8211;6</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">We would like to remind that even at the small quantities used in the practice of ophthalmology&#44; anti-VEGF agents may able to cause serious systemic effects including nephropathy&#46;</p></span>"
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:6 [
            0 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cellular and molecular aspects of diabetic nephropathy&#59; the role of VEGF-A"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46; Carranza"
                            1 => "D&#46; Veron"
                            2 => "A&#46; Cercado"
                            3 => "N&#46; Bautista"
                            4 => "W&#46; Pozo"
                            5 => "A&#46; Tufro"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.nefro.2015.05.013"
                      "Revista" => array:6 [
                        "tituloSerie" => "Nefrologia"
                        "fecha" => "2015"
                        "volumen" => "35"
                        "paginaInicial" => "131"
                        "paginaFinal" => "138"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26300505"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Intravitreal bevacizumab &#40;Avastin&#41; treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "R&#46;F&#46; Spaide"
                            1 => "Y&#46;L&#46; Fisher"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Retina"
                        "fecha" => "2006"
                        "volumen" => "26"
                        "paginaInicial" => "275"
                        "paginaFinal" => "278"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16508426"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration&#58; a meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "W&#46; Wang"
                            1 => "X&#46; Zhang"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1371/journal.pone.0109744"
                      "Revista" => array:5 [
                        "tituloSerie" => "PLOS ONE"
                        "fecha" => "2014"
                        "volumen" => "9"
                        "paginaInicial" => "e109744"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25330364"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Relapse of minimal change nephrotic syndrome after intravitreal bevacizumab"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46; Sato"
                            1 => "Y&#46; Kawasaki"
                            2 => "T&#46; Waragai"
                            3 => "T&#46; Imaizumi"
                            4 => "A&#46; Ono"
                            5 => "N&#46; Sakai"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ped.12017"
                      "Revista" => array:6 [
                        "tituloSerie" => "Pediatr Int"
                        "fecha" => "2013"
                        "volumen" => "55"
                        "paginaInicial" => "e46"
                        "paginaFinal" => "e48"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23782377"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Membranous nephropathy following intravitreal injection of bevacizumab"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "H&#46;R&#46; Anto"
                            1 => "G&#46;F&#46; Hyman"
                            2 => "J&#46;P&#46; Li"
                            3 => "S&#46; Spitalewitz"
                            4 => "D&#46; Thomas"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jcjo.2011.12.024"
                      "Revista" => array:6 [
                        "tituloSerie" => "Can J Ophthalmol"
                        "fecha" => "2012"
                        "volumen" => "47"
                        "paginaInicial" => "84"
                        "paginaFinal" => "86"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22333861"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46; Pell&#233;"
                            1 => "N&#46; Shweke"
                            2 => "J&#46;P&#46; Duong Van Huyen"
                            3 => "L&#46; Tricot"
                            4 => "S&#46; Hessa&#239;ne"
                            5 => "V&#46; Fr&#233;meaux-Bacchi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1053/j.ajkd.2010.11.030"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Kidney Dis"
                        "fecha" => "2011"
                        "volumen" => "57"
                        "paginaInicial" => "756"
                        "paginaFinal" => "759"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21295897"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/20132514/0000003600000006/v1_201702210030/S2013251416301304/v1_201702210030/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35436"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Letters to the Editor"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003600000006/v1_201702210030/S2013251416301304/v1_201702210030/en/main.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251416301304?idApp=UINPBA000064"
]
Share
Journal Information
Vol. 36. Issue. 6.November - December 2016
Pages 583-722
Share
Share
Download PDF
More article options
Vol. 36. Issue. 6.November - December 2016
Pages 583-722
Letter to the Editor
Open Access
Comment on “Cellular and molecular aspects of diabetic nephropathy; the role of VEGF-A”
Comentario a “Cellular and molecular aspects of diabetic nephropathy; the role of VEGF-A”
Visits
5572
Erol Arslan
Corresponding author
earslan89@yahoo.com

Corresponding author.
, Adem Aydın, Şeref Demirbaş, Kenan Sağlam
Department of Internal Medicine, Gülhane Military Medical Academy, Ankara, Turkey
This item has received

Under a Creative Commons license
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
Dear Editor,

We read the published article with the title of ‘Cellular and molecular aspects of diabetic nephropathy; the role of VEGF-A’1 with a great interest and we found worth sharing our clinical observations through a case to contribute to the their determination.

Katherine Carranza et al.1 have stated that the experimental conditions VEGF-A decreased or after treatment with molecules developed against VEGF, it can be observed various pathologic processes such as glomerular basement membrane damage, proteinuria, acute renal failure and thromboembolic events. Monoclonal antibodies that bind the VEGF has long been used in systemic treatment protocol of solid tumors. Recently, by ophthalmologists, intravitreal administration of anti-VEGF agents seen as the primary treatment method in conditions of age- related macular degeneration, diabetic retinopathy, retinal vein occlusion.2 Although systemic side effects are well known with the high dose intravenous use in cancer therapy, almost local side effects were reported associated with intraocular anti-VEGF treatment. However, despite the blood retinal barrier, anti-VEGF agents are detectable in systemic circulation after intraocular administration through uveal vessels or by aqueous humor outflow and might constitutes systemic adverse effect like nephropathy by antagonizing to VEGF-dependent pathway in glomeruli.3

We describe a case of nephrotic syndrome that were unable to detect significant findings for etiology in first research. But with detailed history we found that she had received intravitreal anti-VEGF due to diabetic retinopathy 10 days before the occurrence of symptoms. After the exclusion of other possible causes. We thought anti-VEGF agents might be responsible. In the literature, we found only 3 cases associated with renal toxicity of intraocular anti-VEGF therapy.4–6

We would like to remind that even at the small quantities used in the practice of ophthalmology, anti-VEGF agents may able to cause serious systemic effects including nephropathy.

References
[1]
K. Carranza, D. Veron, A. Cercado, N. Bautista, W. Pozo, A. Tufro, et al.
Cellular and molecular aspects of diabetic nephropathy; the role of VEGF-A.
Nefrologia, 35 (2015), pp. 131-138
[2]
R.F. Spaide, Y.L. Fisher.
Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.
Retina, 26 (2006), pp. 275-278
[3]
W. Wang, X. Zhang.
Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis.
[4]
T. Sato, Y. Kawasaki, T. Waragai, T. Imaizumi, A. Ono, N. Sakai, et al.
Relapse of minimal change nephrotic syndrome after intravitreal bevacizumab.
Pediatr Int, 55 (2013), pp. e46-e48
[5]
H.R. Anto, G.F. Hyman, J.P. Li, S. Spitalewitz, D. Thomas.
Membranous nephropathy following intravitreal injection of bevacizumab.
Can J Ophthalmol, 47 (2012), pp. 84-86
[6]
G. Pellé, N. Shweke, J.P. Duong Van Huyen, L. Tricot, S. Hessaïne, V. Frémeaux-Bacchi, et al.
Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors.
Am J Kidney Dis, 57 (2011), pp. 756-759
Copyright © 2016. Sociedad Española de Nefrología
Download PDF
Idiomas
Nefrología (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?